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Neoplastic cells within individual carcinomas often exhibit con-
siderable phenotypic heterogeneity in their epithelial versus
mesenchymal-like cell states. Because carcinoma cells with
mesenchymal features are often more resistant to therapy and
may serve as a source of relapse, we sought to determine whether
such cells could be further stratified into functionally distinct
subtypes. Indeed, we find that a basal epithelial marker, integrin-
β4 (ITGB4), can be used to enable stratification of mesenchymal-
like triple-negative breast cancer (TNBC) cells that differ from one
another in their relative tumorigenic abilities. Notably, we demon-
strate that ITGB4+ cancer stem cell (CSC)-enriched mesenchymal cells
reside in an intermediate epithelial/mesenchymal phenotypic state.
Among patients with TNBC who received chemotherapy, elevated
ITGB4 expression was associated with a worse 5-year probability of
relapse-free survival. Mechanistically, we find that the ZEB1 (zinc finger
E-box binding homeobox 1) transcription factor activity in highly mes-
enchymal SUM159 TNBC cells can repress expression of the epithelial
transcription factor TAp63α (tumor protein 63 isoform 1), a protein
that promotes ITGB4 expression. In addition, we demonstrate that
ZEB1 and ITGB4 are important in modulating the histopathological
phenotypes of tumors derived from mesenchymal TNBC cells. Hence,
mesenchymal carcinoma cell populations are internally heterogeneous,
and ITGB4 is a mechanistically driven prognostic biomarker that can be
used to identify the more aggressive subtypes of mesenchymal carci-
noma cells in TNBC. The ability to rapidly isolate and mechanistically
interrogate the CSC-enriched, partially mesenchymal carcinoma cells
should further enable identification of novel therapeutic opportunities
to improve the prognosis for high-risk patients with TNBC.
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During the multistep formation of carcinomas, the epithelialcells from which carcinomas arise are known to acquire
multiple changes in cell phenotype that provide various types of
selective advantage during tumor progression (1). Whereas many
of these changes derive from alterations of their genomes, others
are acquired through the expression of previously latent cell-
biological programs; such programs may be activated in response
to signals that carcinoma cells receive from their microenvi-
ronment (1–3). In particular, as occurs in a number of tissues,
epithelial carcinoma cells are able to acquire mesenchymal-like
traits through activation of the cell-biological program termed the
epithelial-to-mesenchymal transition (EMT) (1). Carcinoma cells
that have activated an EMT program often exhibit increased
tumor-initiating capacity as well as enhanced migratory and in-
vasive abilities (1, 4, 5). Furthermore, these more mesenchymal
carcinoma cells often exhibit increased metastatic abilities and
elevated resistance to radiation and chemotherapy (1, 5).
A complex signaling network regulates the induction and sub-
sequent maintenance of EMT programs (1–3, 6). These signals
ultimately converge on a relatively small number of genes encoding
transcription factors (EMT-TFs) that operate as master regulators
of the EMT program, ushering cells from epithelial into more
mesenchymal states (1–3, 6). When expressed experimentally,
the EMT-TFs, such as TWIST (TWIST1; twist family bHLH
transcription factor 1), SNAIL (SNAI1; snail family transcrip-
tional repressor 1), SLUG (SNAI2; snail family transcriptional
repressor 2), and ZEB1 (zinc finger E-box binding homeobox
1), have been shown to activate EMT programs in a variety of
normal and neoplastic epithelial cell types (1–3, 6).
Increasing evidence makes it apparent that the EMT program
does not operate as a binary switch in which individual cells—
both normal and neoplastic—are caused to reside in either an
epithelial or a mesenchymal state (1). Instead, ongoing research
from a number of groups indicates that individual carcinoma cells
can dwell in intermediate states along the epithelial–mesenchymal
spectrum and thus can coexpress epithelial and mesenchymal char-
acteristics in various proportions (1, 7, 8). Although carcinoma cells
with mesenchymal traits are often more invasive, resistant to
chemotherapy, and more likely to be sources of clinical relapse, we
currently lack the ability to clearly identify the more mesenchymal
carcinoma cells that pose the greatest risk to cancer patients, no-
tably those endowed with increased tumor-initiating potential.
The CD44 and CD24 cell-surface markers have been widely
used to resolve epithelial and mesenchymal carcinoma cells (1, 4,
9). Among other uses, these markers have proven useful in
identifying more mesenchymal carcinoma cell populations that
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are enriched in the representation of tumor-initiating cells
(TICs), often termed cancer stem cells (CSCs) (1, 4, 9). How-
ever, these markers have not proven useful in further resolving
the more mesenchymal cells into distinct subpopulations, leaving
unanswered the precise nature of the mammary CSCs, which
usually reside as minority cell populations within larger pop-
ulations of the more mesenchymal cells. For this reason, addi-
tional markers have been sought to complement CD44 and CD24
in the fractionation of carcinoma cell subpopulations (10, 11).
Triple-negative breast cancer (TNBC) represents a subset of
tumors that constitute only 10–15% of all breast cancer, but
accounts disproportionally for greater than one-third of breast-
cancer–related deaths (12). A critical feature of TNBC is abundant
inter- and intratumoral heterogeneity, including mesenchymal
phenotypes revealed by routine histopathological analyses. Un-
fortunately, our ability to resolve these heterogeneous, more
mesenchymal carcinoma cells into distinct subpopulations has
been limited. In light of these challenges, we undertook to identify
additional cell-surface markers that would make it possible to
efficiently resolve functionally important subpopulations from
heterogeneous populations of the more mesenchymal TNBC cells.
In an effort to better resolve the carcinoma cell heterogeneity
often observed in TNBC, we determined that integrin-β4 (ITGB4)
can be used as a marker to identify CSC-enriched populations of
partially mesenchymal carcinoma cells. This result was consistent
with previous mechanistic work, which demonstrated that ITGB4
can promote activation of the MET protooncogene receptor tyro-
sine kinase, epidermal growth factor receptor, focal adhesion kinase,
SRC protooncogene nonreceptor tyrosine kinase, phosphoinositide
3-kinase, AKT serine/threonine kinase (AKT), mitogen-activated
protein kinase kinase 1/2, mitogen-activated protein kinase (ERK)
1/2, and ras homolog family member A signaling pathways that are
known to enhance tumor progression (13–15). Importantly, ITGB4
has been previously shown to be enriched in TNBC breast cancer
patient tissues (16). Moreover, an ITGB4-related 65-gene classifier
has been shown to have prognostic value when used to generally
analyze survival of breast cancer patients (16). We now demonstrate
that ITGB4 mRNA alone can be used to stratify survival for TNBC
patients that require chemotherapy; patients with tumors exhibiting
high levels of ITGB4 mRNA had a significantly worse prognosis.
These results were similar to those that have been reported in
pancreatic ductal adenocarcinoma (17) and non-small cell lung
cancer (18). Together, our results demonstrate that ITGB4 can be
used to identify CSC-enriched TNBC cells and that high levels of
ITGB4 mRNA can be used clinically to identify patients that may
benefit from more aggressive therapeutic strategies.
Results
Expression of ITGB4 on the Surface of Epithelial and Mesenchymal
Subtype Triple-Negative Breast Cancer Cells. Multiple distinct sub-
types of TNBC cells have been described based on global gene
expression analyses (19, 20); however, little information existed in
the literature regarding how such subtypes of TNBC cells could be
grouped or physically segregated based on their cell-surface
marker profiles. To address this issue, we performed a series of
analyses using highly epithelial immortalized mammary epithelial
cells (HMLEs) (21), and their derived naturally arising mesen-
chymal epithelial cell (NAMEC) population, NAMEC8 (22),
which led to the identification of ITGB4 as a cell surface protein
that could be used for fluorescence-activated cell sorting (FACS)
to segregate highly epithelial and mesenchymal-like mammary
epithelial cells according to their relative epithelial versus mes-
enchymal cell states (SI Appendix, Fig. S1, and Datasets S1–S4).
Moreover, segregating mesenchymal-like mammary epithelial
cells using ITGB4 via FACS enabled resolution of two distinct
classes of mesenchymal subtype mammary epithelial cells: an
ITGB4hi fraction that was determined to be more epithelial and an
ITGB4lo fraction that was more highly mesenchymal, despite the
fact that both populations displayed similar overt morphological and
canonical molecular mesenchymal-like phenotypes (SI Appendix,
Fig. S2, and Dataset S4). Importantly, using unsupervised hierar-
chical clustering of their gene expression profiles, the HMLE and
NAMEC8 cells used for these analyses were determined to be more
closely related to triple-negative breast cancer cell lines than other
common breast cancer subtypes (SI Appendix, Fig. S3).
To determine whether ITGB4 would serve as a useful cell-surface
marker for resolving distinct subtypes of TNBC cells, we performed
Western blot and FACS analyses of 10 human TNBC cell lines (Fig. 1
A–C and SI Appendix, Fig. S4B). Our results indicated that, similar to
results obtained using the highly epithelial HMLE cells (SI Appendix,
Fig. S1), ITGB4 was abundantly expressed by the more epithelial
TNBC cell lines (MDA-MB-468, HCC1143, HCC1806, HCC38, and
SUM149), despite their lack of canonical epithelial morphological
characteristics (SI Appendix, Figs. S4C and S8B). Conversely,
ITGB4 was expressed at relatively low levels on the surface of cells
from three of the more mesenchymal TNBC cell lines (MDA-MB-
157, HS578T, and BT549) (Fig. 1 and SI Appendix, Fig. S4).
Importantly, similar to the mesenchymal NAMEC8 cells (SI
Appendix, Figs. S1 and S2), we readily detected ITGB4 expression
on the surface of cells present in two mesenchymal-subtype TNBC
lines, SUM159 and MDA-MB-231 (Fig. 1 C and D and SI Appendix,
Fig. S4B and see Fig. S8A). As revealed by FACS analyses, the
difference of ITGB4 cell-surface abundance between ITGB4hi and
ITGB4lo cells within each of these two TNBC populations ranged
between 10- and 100-fold (Fig. 1 C and D and SI Appendix, Fig. S4B
and see Fig. S8A). This broad spectrum of expression by different
cells within the SUM159 and MDA-MB-231 mesenchymal-subtype
TNBC populations was sufficient in each case for isolation of distinct
ITGB4hi and ITGB4lo subpopulations by FACS (Figs. 1E, 2, and 4).
ITGB4 Identifies CSC-Enriched Mesenchymal TNBC Cells. Of the
mesenchymal-subtype TNBC cell lines that were analyzed by FACS,
cells of the SUM159 line exhibited the greatest degree of segregation
between ITGB4hi and ITGB4lo expression levels, with two distinct
ITGB4hi and ITGB4lo peaks (Fig. 1 C and D). Nonetheless, all of
the cells comprising this cell line shared a common CD44hi pheno-
type (Fig. 1C). This finding caused us to focus in more detail on the
SUM159 cells and the possibility that their outwardly mesenchymal
morphology concealed an underlying variability in the expression
of epithelial and mesenchymal genes and corresponding protein
markers—similar to the nonneoplastic polyclonal NAMEC8 mam-
mary epithelial cells (MECs) we had used in our previous analyses.
We used FACS to fractionate the heterogeneous SUM159 cells
into ITGB4hi and ITGB4lo subpopulations (Figs. 1E and 2A). These
two populations were cultured independently and did not sponta-
neously interconvert over a period of 2 mo in continuous culture.
Canonical markers of the epithelial and mesenchymal state revealed
minor differences between the cells from the perspective of mRNA
expression [less than a fourfold difference for SNAIL, SLUG,
TWIST1, TWIST2, ZEB1, ZEB2, CDH2 (cadherin 2; also known as
N-cadherin), VIM (vimentin), and FN1 (fibronectin)] (SI Appendix,
Fig. S5 A and B). However, whereas FN1 mRNA differed only by
twofold when comparing the two populations, FN1 protein ex-
pression was significantly elevated in the ITGB4lo population
(Fig. 1E). During the first 48 h after each in vitro passage, both
populations exhibited a lack of cell–cell junctions and clustering,
the presence of a front–back polarity, and displayed an elongated
rather than cobblestone morphology (Fig. 2A). However, the
ITGB4lo cells adopted a more spindle-like morphological phe-
notype compared with the ITGB4hi cells (Fig. 2A).
As judged by FACS analyses, the SUM159 ITGB4hi and
ITGB4lo cells differed in their respective CD24 profiles (Fig.
1C). The ITGB4hi population was composed of both CD24hi and
CD24lo cells, whereas the ITGB4lo population was primarily
CD24lo. These results indicated that the CD24 and CD44
markers alone could not be used to isolate the same SUM159
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subpopulations that had been identified using ITGB4. To de-
termine how the SUM159 ITGB4hi and ITGB4lo populations of
mesenchymal carcinoma cells related to one another using an
unbiased approach, we performed RNA-sequencing (RNA-seq)
analyses (Fig. 2B and SI Appendix, Figs. S5 A and D and S6A and
Dataset S5), and compared the differentially expressed genes with
an EMT-associated gene expression profile identified using the
highly epithelial HMLE and more mesenchymal NAMEC8 cells
(Fig. 2B and SI Appendix, Fig. S5D and Datasets S1, S5, and S6).
The SUM159 ITGB4lo mesenchymal carcinoma cells exhibited
levels of EMT-associated gene expression that were higher (ranging
from 3- to >500-fold) than the ITGB4hi mesenchymal carcinoma cells
(SI Appendix, Figs. S5 C and D and S6A and Datasets S5 and S6).
These results confirmed the utility of ITGB4 as a marker to separate
more epithelial from more mesenchymal subpopulations of CD44hi
mesenchymal-like human mammary carcinoma cells and suggested
that it could be used to determine whether the distinct subpopulations
differ from one another in their relative tumor-initiating abilities.
As a prelude to tumor initiation studies, we determined that
the ITGB4hi and ITGB4lo cells had equivalent proliferation rates
and tumorsphere-forming abilities in culture (SI Appendix, Fig.
S6E). We proceeded to determine whether either of the two
SUM159 subpopulations was enriched in traits associated with
CSCs by implanting these cells at limiting dilutions in nonobese
diabetic (NOD)/severe combined immunodeficient (SCID) host mice
to gauge their relative tumor-initiating abilities (Fig. 2C). The paren-
tal, unfractionated SUM159 cells exhibited a calculated TIC frequency
of 1/42,942 cells. Cells of the ITGB4hi subpopulation were more ef-
ficient in tumor initiation, with a TIC frequency of 1/14,679 in contrast
to the TIC frequency of 1/199,348 for the ITGB4lo cell population, i.e.,
essentially a >10-fold difference in the representation of TICs. This
finding indicated that, in addition to its display of multiple mesen-
chymal traits, the TIC-enriched fraction expressed a significant level
of an epithelial marker—ITGB4—and accordingly, resided in an in-
termediate state between fully epithelial and fully mesenchymal.
We next determined whether the behavior of the SUM159 cells,
as described above, was echoed by that of other neoplastically
transformed cell lines. Thus, we performed similar experiments using
variants of mesenchymal-like epithelial cells that had been derived
from transformation of three different NAMEC lines through in-
troduction of an HRAS oncogene (NAMECR; Fig. 3 and SI Ap-
pendix, Fig. S7). Because it was known that expression of this
oncogene can itself alter the epithelial versus mesenchymal mor-
phological and molecular phenotype of transformed cells (SI Ap-
pendix, Fig. S7) (23), we normalized the cells for expression of
the HRAS oncogene-expressing retroviral construct, which also
Fig. 1. Characterization of ITGB4 expression in a panel of TNBC cell lines and isolation of SUM159 ITGB4hi and ITGB4lo cell populations. (A) Western blot
analyses for 10 triple-negative breast cancer (TNBC) cell lines that have been previously characterized using the PAM50 strategy into basal A and basal B
subtypes or according to the strategy outlined by Lehmann et al. (19, 20) into basal-like (BL1/BL2) and mesenchymal/mesenchymal stem-like (M/MSL) subtypes.
(B) FACS histograms of ITGB4 in eight TNBC cell lines. (C) CD44, CD24, and ITGB4 FACS profiles of the SUM159 cell line. (D) Typical histogram of the SUM159
cells used to isolate ITGB4hi and ITGB4lo subpopulations. (E) Western blots of fibronectin (FN1) and cytochrome c oxidase subunit 4I1 (COXIV) for SUM159 cells
and the derived ITGB4hi and ITGB4lo subpopulations.














included an internal ribosome entry site (IRES) to drive green fluo-
rescent protein (GFP) expression (IRES-GFP), doing so via FACS
for GFP and monitoring the levels of ITGB4 expression following
transformation (Fig. 3A).We also monitored the expression of several
EMT markers [ZEB1, FN1, VIM, CDH1 (cadherin 1; also known as
E-cadherin), CDH3 (cadherin 3; also known as P-cadherin)], and
TP63 (tumor protein 63) and RAS-activated proteins (AKT and
ERK1/2) by Western blot analyses (Fig. 3B), which demonstrated
negligible differences between the NAMEC1R, NAMEC5R, and
NAMEC8R cell lines in vitro. Using these NAMECR cell lines, we
determined that the NAMEC8R line, which contained a large pro-
portion of cells with a CD44hiCD24loITGB4hi cell-surface profile, was
significantly better at initiating tumors than its more highly mesen-
chymal CD44hiCD24loITGB4lo counterparts (Fig. 3C). Specifically,
Fig. 2. Molecular and functional characterization of isolated ITGB4hi and ITGB4lo subpopulations of SUM159 TNBC cells. (A) Morphological appearance of
SUM159 ITGB4hi and ITGB4lo cells. (B) Heat maps of genes differentially expressed in the SUM159 ITGB4hi and ITGB4lo cells and the genes that were coordinately
differentially expressed in the HMLE vs. NAMEC8 comparisons used to classify the relative epithelial vs. mesenchymal status of the SUM159 ITGB4hi and ITGB4lo
cells. (C) Tumor-initiating cell (TIC) limiting-dilution assays (LDAs) using the SUM159 cell line and derived SUM159 ITGB4hi or ITGB4lo subpopulations.
Fig. 3. ITGB4 identifies cancer stem cell-enriched populations of engineered mesenchymal mammary carcinoma cells. (A) FACS profiles of HRASG12V and
ITGB4 expression for the NAMEC1R, NAMEC5R, and NAMEC8R cell lines. (B) Western blots of EMT- and RAS-signaling–associated markers. (C) Tumor-initiating
cell (TIC) limiting-dilution assays (LDAs) using the NAEMC1R, NAMEC5R, and NAMEC8R cell lines.
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the highly mesenchymal CD44hiCD24loITGB4lo NAMEC1 and
NAMEC5 cells (Fig. 3B and SI Appendix, Fig. S7 F–H and Dataset
S7), when transformed by RAS (NAMEC1R and NAMEC5R;
SI Appendix, Fig. S7I), were poorly tumorigenic (TIC frequency of
1/692,461 cells) and nontumorigenic, respectively, whereas the het-
erogeneous mesenchymal NAMEC8R population exhibited a TIC
frequency of 1/3,095 cells (Fig. 3C). Once again, cells coexpressing
both epithelial and mesenchymal markers exhibited an elevated tu-
mor-initiating ability, in this instance via a factor of >200 relative to
the more mesenchymal ITGB4lo cells.
Taken together, these results indicated that the more epithelial
ITGB4hi subpopulation of outwardly mesenchymal epithelial cells
exhibited a far higher tumor-initiating ability than the more highly
mesenchymal ITGB4lo cells. Hence, our data demonstrated that
use of ITGB4 as a marker, on its own, allowed stratification of
distinct subpopulations of mesenchymal-subtype TNBC cells and
experimentally transformed populations of naturally arising mes-
enchymal epithelial cells. Importantly, these analyses identified
TIC-enriched subpopulations that could not be clearly identified
by use of the CD44 and CD24 markers alone. Moreover, these
results further support and extend less direct findings of others,
indicating that carcinoma cells that reside in an excessively mes-
enchymal state are actually less efficient in tumor initiation than
their more epithelial counterparts (1, 24).
Intermediate Levels of ITGB4 Identify CSC-Enriched TNBC Cells When
Comparing Mesenchymal MDA-MB-231 and SUM159 Carcinoma Cell
Lines. To begin, we subjected ITGB4hi and ITGB4lo MDA-MB-
231 subpopulations to RNA-seq analyses and limiting-dilution
tumor initiation assays (Fig. 4 A–C and SI Appendix, Fig. S8 and
Dataset S8). Similar to the observations described above, the
mesenchymal MDA-MB-231 CD44+CD24loITGB4hi cells were
more epithelial than their CD44+CD24loITGB4lo counterparts
(Fig. 4B and SI Appendix, Fig. S8D and Datasets S8 and S9).
Of note, the ITGB4hi MDA-MB-231 cells expressed higher levels
of SNAI2 (SLUG) mRNA, reminiscent of normal differenti-
ated human and mouse basal mammary epithelial cells (25, 26),
whereas the more mesenchymal ITGB4lo cells expressed nearly
undetectable levels of SLUG (Fig. 4B). This finding supported the
notion that endogenous SLUG expression was associated with
the more differentiated basal epithelial rather than more
mesenchymal cell state (26). The ITGB4hi MDA-MB-231 cells
also expressed higher mRNA levels of other more epithelial
genes, including CDH1, CDH3, EpCAM (epithelial cell adhe-
sion molecule), and MUC1 (mucin 1, cell surface associated)
(Fig. 4B), further indicating that they exhibited a more epi-
thelial molecular phenotype than their more mesenchymal
ITGB4lo MDA-MB-231 counterparts.
We proceeded to perform limiting-dilution tumor initiation
assays to determine the TIC frequencies of the ITGB4hi and
ITGB4lo MDA-MB-231 cell populations (Fig. 4C). Here we found
that the ITGB4lo MDA-MB-231 cells were more tumorigenic than
the more epithelial ITGB4hi mesenchymal MDA-MB-231 cells
(TIC frequencies of 1 in 13,401 and 1 in 114,341 cells, respec-
tively). Hence, in this particular case, and in contrast with our
previous experience with SUM159 cells described above, the
more mesenchymal cells exhibited a significantly higher degree
of tumorigenicity.
Fig. 4. Molecular and functional characterization of ITGB4hi and ITGB4lo MDA-MB-231 cells and comparison with ITGB4hi and ITGB4lo SUM159 cell pop-
ulations. (A) Heat map of genes differentially expressed in MDA-MB-231 ITGB4hi and ITGB4lo cell populations. (B) Fold change of RNA-seq values comparing
MDA-MB-231 ITGB4hi and ITGB4lo cell populations. (C) Tumor-initiating cell (TIC) limiting-dilution assays (LDAs) using the MDA-MB-231 ITGB4hi and ITGB4lo
cell populations. (D) Western blot analyses comparing SUM159 ITGB4hi and ITGB4lo cell populations to MDA-MB-231 ITGB4hi and ITGB4lo cell populations.
(E) Working model representing TNBC partially mesenchymal carcinoma cell enrichment of cancer stem cell (CSC) populations relative to polyclonal bulk cell
populations (PolyCP) that span different regions along the epithelial–mesenchymal cell state spectrum.














To determine how the absolute abundance of ITGB4 from
isolated SUM159 and MDA-MB-231 populations compared with
one another, we performed Western blot analyses (Fig. 4D).
When comparing these four subpopulations (i.e., the two SUM159
and the two MDA-MB-231 subpopulations), the SUM159 ITGB4lo
cells had the least ITGB4 protein, whereas the MDA-MB231
ITGB4hi cells had the most (Fig. 4D). The remaining two pop-
ulations, SUM159 ITGB4hi and MDA-MB-231 ITGB4lo, which
carried in each case the great bulk of the CSCs, expressed in-
termediate levels of ITGB4 (Fig. 4D). Taken together, the
SUM159 and MDA-MB-231 data indicated that, in the case of
these two polyclonal mesenchymal populations, cells with an
intermediate level of ITGB4 expression exhibited a hybrid epi-
thelial/mesenchymal phenotype and were more tumorigenic than
their isogenic counterparts that resided in either a more com-
plete epithelial or mesenchymal cell state (illustrated in Fig. 4E).
Correlation of ITGB4 mRNA Expression with Decreased Relapse-Free
Survival in Patients with TNBC. TNBC tumors are defined clinically by
the absence of immunohistochemical staining for the estrogen re-
ceptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2). TNBCs are highly overlapping
with the molecular basal-like subtype, defined through mRNA ex-
pression profiling and use of the PAM50 classification strategy (27,
28). To assess the potential clinical impact of ITGB4 marker ex-
pression in patients with TNBC, we evaluated ITGB4 mRNA ex-
pression in tumor biopsies obtained at the time of diagnosis and
determined the association of this expression with relapse-free sur-
vival (RFS) in clinically defined TNBC and molecular basal-subtype
patient cohorts, doing so using previously reported global gene ex-
pression patterns determined by mRNAmicroarray analyses (29, 30).
Among patients with TNBC who received chemotherapy, those
whose tumors exhibited high levels of ITGB4 RNA (biopsied at
the time of diagnosis) experienced a significantly lower probability
of 5-year relapse-free survival relative to those whose tumors
displayed low levels of ITGB4 RNA (Fig. 5 and SI Appendix, Fig.
S9). This finding was true in both the clinically defined TNBC and
molecular basal-subtype cohorts. These correlations were based
on analyses conducted using two independent datasets (29, 30).
In the Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) dataset (Fig. 5 A and B and SI Ap-
pendix, Dataset S10) (29), the hazard ratio (HR)—a metric that
describes the fold increase in risk for relapse over time—between
the two groups was 1.67 [95% confidence intervals (CI) 1.0–2.8]
with a log rank P value of <0.05, and a HR 1.89 (95% CI 1.15–
3.11) with a log rank P value of <0.01, for the clinically defined
and molecular basal-subtype cohorts, respectively. As a sensi-
tivity analysis, we performed a multivariate analysis of ITGB4
expression and RFS, including primary tumor stage, histologic
grade, and patient age, which resulted in nearly identical hazard
ratios in clinically defined TNBC (HR 1.70; 95% CI 0.93–3.10,
P = 0.086) and basal-subtype (HR 1.97; 95% CI 1.11–3.52, P =
0.01) cohorts, despite lower statistical power. In the dataset gen-
erated by Györffy, et al. (30), the hazard ratio was 3.3 (95% CI
1.16–9.4), with a log rank P value of <0.02, for the clinically defined
chemotherapy-treated TNBC cohort (SI Appendix, Fig. S9A).
Hence, in two independent datasets, high levels of ITGB4 corre-
lated with a poor outcome in patients whose tumors required
chemotherapy. In contrast, within cohorts of TNBC and molecular
basal-subtype patients whose tumors did not receive or require
chemotherapy, there was no significant difference in RFS between
those that exhibited high or low levels of ITGB4 mRNA in tumor
biopsies prepared at the time of diagnosis (Fig. 5B).
The results demonstrating stratification of patients with TNBC
based on ITGB4 mRNA into groups that differed in their prob-
ability of relapse-free survival led us to test whether this correla-
tion was observed in other solid tumor types. Specifically, we
found that higher levels of ITGB4 mRNA also correlated with a
decreased probability of progression-free survival in patients with
lung adenocarcinoma, stage 4 serous ovarian cancer, and gastric
cancer (SI Appendix, Fig. S9 B–D). These results provide initial
evidence suggesting that the results of our TNBC analyses may
prove to be applicable to carcinomas arising in other tissues.
The observed difference in clinical outcome, for ITGB4hi and
ITGB4lo chemotherapy-treated breast cancer patients, prompted
us to determine whether the two classes of CD44hi mesenchymal
carcinoma cells, ITGB4hi and ITGB4lo, exhibited a differential
cell-intrinsic response in culture to a broad range of common
chemotherapeutic and antineoplastic small molecule compounds.
To do so, we performed a five-point dose–response screen of 392
Fig. 5. Clinical correlations between ITGB4 mRNA expression and patient relapse-free survival in triple-negative and molecular basal subtype breast cancer.
(A) Kaplan–Meier survival curves for patients in the upper quartile of ITGB4 expression compared with those in the lower three quartiles. (B) Statistical details
related to survival correlations conducted for ITGB4 expression in the METABRIC analyses. HR, hazard ratio; p, log rank P value.
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compounds, including many common chemotherapeutics as well
as other small molecule inhibitors of cancer-associated pathways
to compare the viability of SUM159 ITGB4hi and ITGB4lo mes-
enchymal carcinoma cells after a 72-h period of treatment (SI
Appendix, Dataset S11). The results indicated no clinically signif-
icant difference in sensitivity to the tested compounds by the
SUM159 ITGB4hi or ITGB4lo populations. When taken together
with the survival outcome analyses, these data suggested that one
possible explanation of the poor prognosis for patients with
ITGB4hi tumors, supported by our data in TNBC, is that among
cells that escape therapy, the increased frequency of CSCs present
in mesenchymal ITGB4hi TNBC populations can contribute to the
higher frequency of relapse observed in the clinic.
ITGB4hi and ITGB4lo Mesenchymal Carcinoma Cells Harbor CSCs That
Give Rise to Distinct Histopathological Phenotypes During Tumor
Progression. The above observations indicated that residence of
carcinoma cells in a highly mesenchymal ITGB4lo cell state was
negatively correlated with tumor-initiating ability. However,
clinically, the histopathology of a tumor, rather than an estima-
tion of CSC frequency, is used as a parameter to inform decisions
related to therapeutic strategies aimed at managing disease
progression. Hence, we examined histological sections of the
tumors generated above and found that the SUM159 cell line
demonstrated the most robust difference in features that could
distinguish the ITGB4hi and ITGB4lo subtypes. Specifically, tu-
mors derived from the ITGB4hi SUM159 cells were composed
predominantly of carcinoma cells with large hyperchromatic nuclei
(Fig. 6A), whereas the rarely observed tumors derived from
ITGB4lo cells had relatively small pleomorphic nuclei (Fig. 6A).
The ITGB4hi carcinoma cells primarily existed in clusters with
sparse matrix deposition, whereas the ITGB4lo tumors exhibited
interwoven fascicles of cells with a more mesenchymal, spindle-
like morphology and abundant matrix deposition (Fig. 6A). The
tumors derived from ITGB4hi cells also exhibited an increase in
the abundance of polymorphonuclear immune cell infiltration
compared with those derived from ITGB4lo cells (Fig. 6A).
The observed differences in matrix deposition and immune in-
filtration correlated well with RNA-seq data generated from analyses
of these two populations growing in monolayer culture (SI Appendix,
Dataset S5). Thus, the more mesenchymal ITGB4lo cells expressed
higher levels of mesenchymal-like extracellular-matrix–associated
Fig. 6. Histopathological analyses and identification of a ZEB1–TAp63α–ITGB4 axis in SUM159 ITGB4hi and ITGB4lo cell populations. (A) H&E-stained histo-
logical sections of tumors derived from SUM159 ITGB4hi and ITGB4lo cells. (B and C) Western blots for ITGB4, ZEB1, FN1, TAp63α, and COXIV in the sorted and
CRISPR-Cas9-sg engineered cell lines. (D) H&E-stained histological sections of tumors derived from SUM159 ITGB4lo cells that either lacked ZEB1 or ectopically
expressed ITGB4.














genes, whereas the ITGB4hi cells were enriched for expression of
immune-associated cytokine genes. Accordingly, the distinct histo-
pathology of these two classes of tumors reflected a profound dif-
ference in underlying gene expression.
Mechanistic Analyses of a ZEB1–TAp63α–ITGB4 Axis Reveal an
Essential Role for ZEB1 and ITGB4 in Dictating the Pathological
Behavior of Highly Mesenchymal CSCs. Based on our results dem-
onstrating unique pathological behaviors of CSCs present in the
SUM159 ITGB4hi and ITGB4lo mesenchymal carcinoma cell
populations, we examined whether certain molecular mecha-
nisms could be identified that underlay the highly mesenchymal
histopathological phenotype of tumors derived from the more
mesenchymal carcinoma cells compared with those derived from
the more epithelial subtype of mesenchymal carcinoma cells.
Thus, we noted that ZEB1 was the only EMT-TF commonly
expressed in all five of the mesenchymal subtype TNBC cell lines
that we had analyzed (Fig. 1A). This finding suggested its es-
sentiality in maintaining the residence of these cells in the highly
mesenchymal ITGB4lo cell state and the possibility that it might
contribute to the histopathological phenotype of tumors derived
from these cells in vivo.
To test this notion, we performed tumor induction assays using
SUM159 ITGB4lo cells that had undergone CRISPR-mediated
deletion of ZEB1 (Fig. 6 B and D and SI Appendix, Fig. S10A).
Indeed, loss of ZEB1 in these ITGB4lo TNBC cells, propagated
in vitro, resulted in their conversion to a more epithelial ITGB4hi
FN1lo cell state (Fig. 6B and SI Appendix, Fig. S10A). The shift
from a more mesenchymal to a more epithelial state was ac-
companied by induction of the epithelial marker TAp63α (tumor
protein 63 isoform 1) (Fig. 6B), a transcription factor that has
previously been characterized as a positive regulator of ITGB4
expression (31). This finding was consistent with our observa-
tions that, prior to ablation of ZEB1, the expression of TAp63α
was robustly expressed by the ITGB4hi cells, whereas the ITGB4lo
population had almost no detectable expression (Fig. 6 B and C).
Thus, we tested the relevance of TAp63α expression on the reg-
ulation of ITGB4 and FN1 expression in the SUM159 ITGB4hi
cells (Fig. 6C and SI Appendix, Fig. S10B). Indeed, ablation of
TAp63α in the SUM159 ITGB4hi cells had no impact on ZEB1
expression, but significantly decreased ITGB4 expression (>10-
fold) and increased the expression of the mesenchymal marker,
FN1 (Fig. 6C). Together, these results indicated that loss of ZEB1
shifted the highly mesenchymal ITGB4lo cells toward a more
epithelial cell state and that this was in part due to the loss of
ZEB1-dependent TAp63α repression.
When injected into mice, the ZEB1 knockout ITGB4lo cells
initiated tumors that were compared with those derived from the
ITGB4hi, ITGB4lo, and nontargeting CRISPR control ITGB4lo
cells to determine their relative histopathological phenotypes. In
tumors derived from ITGB4lo cells that lacked ZEB1, the car-
cinoma cells exhibited a broad range of more epithelial histo-
morphological phenotypes (Fig. 6D). These results indicated that
endogenous ZEB1 was required to maintain ITGB4lo TNBCs in
a highly mesenchymal cell state, and indeed, was a critical reg-
ulator of the highly mesenchymal histopathological phenotype of
the resulting tumors.
Based on the molecular and phenotypic alterations that we
had observed and the known role of ZEB1 as a centrally acting
EMT-TF, we presumed that the loss of ZEB1 would lead to a
broad spectrum of alterations within these cells. Indeed, ITGB4
itself has been shown to be transcriptionally repressed by ZEB1
(32), and ITGB4 has been shown to promote tumor progression
in a number of previously published studies (13). Accordingly, we
speculated that ectopic expression of ITGB4 in the SUM159
ITGB4lo cells might, on its own, alter the histopathological
phenotype of tumors arising from these carcinoma cells. To test
this notion, we constitutively expressed ITGB4 in the SUM159
ITGB4lo cells (SUM159 ITGB4OE) at a similar level to that
observed in the SUM159 ITGB4hi cells and used these SUM159
ITGB4OE cells to generate tumors (Fig. 6D and SI Appendix, Fig.
S10 C and D). Notably, forced expression of ITGB4 in the
SUM159 ITGB4lo cells on its own caused them to form tumors
displaying a histopathological phenotype that closely resembled
the more epithelial phenotype observed in the naturally arising
SUM159 ITGB4hi tumors (Fig. 6D).
Taken together, these observations indicated that levels of
ITGB4 expression can serve as a useful marker in revealing
residence of cells in more epithelial or mesenchymal states, and
that its expression could contribute to the histopathological
phenotype observed during tumor progression. Moreover, be-
cause ITGB4 mRNA could stratify TNBC patient cohorts into
groups that differed in their probability of relapse, ITGB4 could
be considered a mechanistically driven prognostic biomarker,
which is by definition, a prognostic biomarker with the ability to
regulate the pathogenesis of disease progression.
Discussion
Intratumoral carcinoma cell heterogeneity has been widely ob-
served and studied in various ways to identify CSC-enriched
subpopulations and determine their differential susceptibilities
to various treatment modalities (5). In the case of carcinomas,
one major source of heterogeneity, which has been the focus of a
large body of research over the past decade, derives from dif-
ferences between carcinoma cells that reside in epithelial versus
mesenchymal cell states (1, 11, 24, 33, 34). Indeed, conversions
between these states have been shown to occur as a result of
activating cell-biological programs that result in epithelial-to-
mesenchymal and mesenchymal-to-epithelial transitions. As we
and others have shown, activation of an EMT program fosters
entrance of both normal and neoplastic mammary epithelial cells
into stem-cell states (1, 25, 26, 35). Importantly, carcinoma cells
within the mesenchymal-like CD44hiCD24lo state are generally
more tumorigenic and more resistant to radiation and chemo-
therapy than those in a more epithelial CD44loCD24hi cell state
(4, 5, 9, 11, 22, 36). However, very little has been reported about
the tumorigenicity or therapeutic susceptibility of different subtypes
of mesenchymal-like mammary carcinoma cells that reside within
the larger population of these more mesenchymal carcinoma cells.
In the case of breast cancer, a growing number of cell-surface
and intracellular markers have been used for the identification of
different types of CSCs (1, 5, 11). Whereas many of the identi-
fied markers can enrich for stem-like carcinoma cell populations,
additional markers are needed to enable more precise, focused
analyses of CSCs. Here we identify a marker, ITGB4, otherwise
known as CD104, that serves both in immortalized basal-like
human MECs and in TNBC cells as a readout, indicating the
extent to which the mesenchymal-like cells have proceeded
through EMT programs. This utility may be due, in part, to the
fact that the ITGB4 gene promoter is directly targeted and re-
pressed by several of the EMT-TFs, which are known to be re-
sponsible for orchestrating EMT programs (32, 37, 38). Using
this indicator function of ITGB4 has allowed us to resolve dis-
tinct subtypes of mesenchymal-like cell subpopulations, which
share in common a CD44hi marker state and exhibit certain
mesenchymal characteristics. As our evidence shows, this outward
similarity in phenotype obscures an underlying heterogeneity.
Thus, we were able to resolve in one case (MDA-MB-231) cells
with an intermediate level of ITGB4 from their more epithelial,
less tumorigenic ITGB4hi counterparts and, in other cases,
SUM159 and NAMECR, cells with an intermediate level of
ITGB4 from their more mesenchymal, less tumorigenic ITGB4lo
counterparts.
These findings provide a direct demonstration that an im-
portant class of CSCs present in heterogeneous basal mammary
carcinoma populations resides in a partially epithelial/partially
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mesenchymal state rather than the fully mesenchymal state that
might be inferred simply from their CD44hiCD24lo cell-surface
profile. Nonetheless, use of this ITGB4/CD104 marker only allowed
us to enrich for the presence of tumor-initiating cells, i.e., CSCs, and
further stratification of CD44hiCD24lo mesenchymal carcinoma
cells exhibiting an intermediate level of ITGB4 expression will be
required to isolate pure populations of mammary CSCs.
These observations hold implications for the nature of CSCs.
Thus, activation of an EMT program appears to be productive
for generating CSCs if it permits carcinoma cells to acquire
certain mesenchymal traits, while retaining certain epithelial
characteristics (1, 11, 24, 34, 39). This finding would explain why
forced entrance of epithelial cells into a fully mesenchymal state
is actually counterproductive for the formation of CSCs; we
suspect that similar rules apply to normal nonneoplastic epi-
thelial cells and their corresponding subpopulations of SCs.
Together these observations, as summarized in Fig. 4E, indicate
that an important class of TNBC CSCs resides in an intermediate
state between highly epithelial and highly mesenchymal and that
residence in either a highly epithelial or a highly mesenchymal
state is less compatible with tumor-initiating capability.
Despite remarkable progress over the past decade in defining
inter- and intratumoral heterogeneity in TNBC, few prognostic
biomarkers are routinely used in clinical practice. Clinicopath-
ologic characteristics of TNBC (stage, grade, and patient age)
and response to neoadjuvant chemotherapy are routinely used
without additional immunohistochemical, genomic, or expres-
sion-based biomarkers. Importantly, high levels of ITGB4
mRNA expression in biopsy samples at the time of diagnosis
significantly correlated with reduced relapse-free survival in pa-
tients with TNBC who received chemotherapy. These findings
are consistent with our observations that ITGB4 is expressed by
mesenchymal TNBC cell populations containing high numbers
of CSCs and suggest that ITGB4 should be investigated as a
mechanistically driven prognostic biomarker in patients with
high-risk TNBC.
To determine whether these results could be applicable to
other types of cancer, we performed analyses using ITGB4
mRNA expression levels and progression-free survival in pa-
tients with lung adenocarcinoma, stage 4 serous ovarian cancer,
and gastric cancer. These results, similar to those in TNBC, in-
dicated that in all three types of cancer, higher levels of ITGB4
mRNA correlated with decreased progression-free survival for
patients. Thus, the results reported in TNBC might be con-
ceptually and fundamentally important for identifying and in-
terrogating CSC-enriched populations of carcinoma cells that
arise in other tissues and organs. With the identification of pro-
teins and pathways that critically regulate the functional abil-
ities of CSC-enriched populations, including and beyond those
related to the ZEB1, p63, and ITGB4 proteins that we have
initially assessed, it may be possible to design more effective
strategies for therapeutically targeting these cells in patients.
Materials and Methods
Cell Lines and Culture Conditions. HMLE and NAMEC based cell lines were
cultured essentially as previously described using MEGM medium (21). MDA-
MB-157, MDA-MB-231, HCC38, HCC1806, HCC1143, HS578T, BT549, MDA-
MB-468, SUM159, and SUM149 cell lines were cultured using media outlined
in SI Appendix. All cell lines were maintained in subconfluent conditions and
media were replenished every 48 h.
Plasmid Constructs and Virus Production. pLenti-CRISPR-Cas9 V2 (Addgene
52961) constructs were produced as previously described (40) using sequences
outlined in SI Appendix. Due to the altered expression of ITGB4 resulting
from use of the sgZEB1 and sgTP63 constructs, cells were FACS sorted on
ITGB4 to obtain the respective knockout populations used for subsequent
analyses. The pLXSN-ITGB4 construct used to create the SUM159lo ITGB4OE
cell line was generously provided by the laboratory of Arthur M. Mercurio
(University of Massachusetts, Worcester, MA). pLenti-based constructs were
packaged with the pMD2.G (VSVG) and psPAX2 plasmids (Addgene 12259 and
12260, respectively). pLXSN-ITGB4 was packaged with pUMVC (Addgene
8449) and pMD2.G. Viral infections were performed using 6 μg/mL prot-
amine sulfate for 8 h.
FACS Analyses and Sorting. Cells were prepared for sorting following tryp-
sinization and quenching in Dulbecco’s modified Eagle’s medium (DME)
supplemented with 10% (vol/vol) inactivated fetal calf serum (IFS). For FACS
analyses and sorting, cells were resuspended in ice-cold PBS− + 2% IFS at 1 × 106
cells per 100 μL. FACS antibodies were added with a 1:100 dilution. All
FACS-sorted cell populations were obtained by starting with the top and
bottom 2.5% of the ITGB4 FACS histograms for the first round, followed by
5 and 25% cutoffs for the second and third rounds of sorting. Cell lines
were allowed a period of at least two passages after the final sort to
minimize nonspecific differences between the populations attributed to
the process of sorting. Antibodies used for FACS sorting and analyses are
outlined in SI Appendix. Aldefluor assays were conducted essentially as
described by the manufacturer (Stemcell Technologies; 01700).
Proliferation and Tumorsphere Assays. Proliferation assays were conducted in
96-well plates using CyQuant (Thermo Fisher Scientific, C7026), according to
the manufacturer’s recommendations, to measure DNA content in each well
during a 4-d time course. The first day after seeding was counted as T = 0
and used for normalization of values obtained from plates collected at
subsequent time points. Tumorsphere assays were conducted using the
MammoCult Medium Kit (Stemcell Technologies, 05620) supplemented
with 4 μg/mL heparin, 0.48 μg/mL hydrocortisone, penicillin/streptomycin,
and 1% methylcellulose.
Tumor Induction and Limiting Dilution Analyses. Orthotopic xenografts were
performed via injection into the fourth inguinal mammary fat pad of NOD/
SCID mice using cells resuspended in a 50% growth factor reduced Matrigel
and PBS solution. Mice were monitored twice a week for a total of 8 wk
following the procedure. Tumor initiating cell frequencies were calculated
using the extreme limiting dilution analysis (ELDA) algorithm as previously
described (41). Tumors were collected and sliced into ∼2.5-mm sections and
fixed in 10% neutral buffered formalin. H&E-stained 5-μM sections of fixed
tumor tissues were imaged using a Leica Biosystems Aperio digital slide
scanner.
Western Blot Analyses. To prepare protein, cells were washed twice with ice-
cold PBS− and placed on ice. Ice-cold lysis buffer [50 mM Tris pH 7.5, 150 mM
NaCl, 10 mM EDTA pH 8.0, 0.2% sodium azide, 50 mM NaF, 0.5% Nonidet
P-40, proteinase inhibitor mixture (1:100; Sigma P8340), phosphatase mix-
ture 2 (1:100; Sigma P5726), and phosphatase inhibitor mixture 3 (1:100;
Sigma P0044)] was used to prepare protein lysates. Western blots were run
using 1× MOPS buffer and NuPAGE Novex 4–12% Bis-Tris gels as described
by the manufacturer (Thermo Fisher Scientific) and transferred to PVDF
membranes. Antibodies and conditions are outlined in SI Appendix.
RNA Preparation, Quantitative Real-Time PCR, and RNA-Seq. Total RNA was
prepared using a modified TRIzol (Thermo Fisher Scientific) protocol. To
prepare total RNA, 1mL of TRIzol reagent was added to a subconfluent 10-cm
dish of cells, scraped, then placed in a microfuge tube. Microfuge tubes were
flash frozen on dry ice. Samples were then thawed and 200 μL of chloroform
was added to each tube, shaken vigorously by hand for 15 s, and incubated
at room temperature for 3 min, then centrifuged at 13,000 × g for 15 min.
The aqueous phase was removed and placed into a gDNA elimination col-
umn from the RNeasy Plus kit (Qiagen). The eluate was mixed at a 1:1 ratio
with 70% RNase-free EtOH and purified following the remaining steps
outlined in the RNeasy Plus kit. cDNA was prepared using the Applied Bio-
systems kit (4368814) as described by the manufacturer with an RNase in-
hibitor (New England Biolabs, M0297L), and using OligodT primers (Thermo
Fisher Scientific, NC9564171). Quantitative real-time PCR was performed
using a Roche Diagnostics LightCycler 480 II and SYBR Green Mastermix
(Roche Diagnostics, 04887352001). Primers used for analysis are outlined in
SI Appendix. RNA-seq libraries were prepared using the TruSeq-stranded
polyA mRNA kits as described by the manufacturer (Illumina, RS-122-2101).
Libraries were pooled and sequenced using a HiSEq 2500. RNA-seq reads
from Illumina 1.5 encoding were aligned using TopHat (v 2.0.13) (42) to the
human genome (GRCh37) with Ensembl annotation (GRCh37.75) in gtf for-
mat. Differential expression was assayed using HTSeq count (43) with pa-
rameters: -m intersection-strict, --strand=reverse, and DESeq2 (44). Cluster3
was used to perform unsupervised hierarchical clustering and the results
were visualized using Java Treeview (45, 46).














Bioinformatic Analyses. Primary patient survival correlations for TNBC and
molecular basal subtype breast cancer were performed using normalized
gene expression data from METABRIC (29) and obtained from the publicly
available European Genome-Phenome Archive (IDs EGAD00010000210 and
EGAD0001000021) (47). Detailed analytical methods for the METABRIC com-
parisons are outlined in SI Appendix. A secondary validation of METABRIC
data and analyses of survival in lung adenocarcinoma, stage 4 ovarian cancer,
and gastric cancer were performed using the kmplot tool (30). Detailed
analytical methods for the conditions used for these comparisons are
outlined in SI Appendix.
Small Molecule Screening. Small molecule screeningwas conducted essentially
as previously described (48). Briefly, cells were plated at a density of 1 × 103
cells per well in 384-well opaque, white assay plates (Corning) with a volume
of 50 μL per well. Cells were incubated overnight and compounds were
added the next day. Compound stocks from the Cambridge Cancer Collec-
tion (Selleck Chemicals) were plated in the 384-well format using five-point,
10-fold concentration ranges, starting at 10 μM. A total of 50 nL of com-
pounds were pin transferred (V&P Scientific, pin tool mounted on a Tecan
Freedom Evo 150 MCA96 head, Tecan) into duplicate assay plates and
incubated for 72 h. DMSO content was 0.1% within each well. On each plate,
16 wells of DMSO vehicle control were used for normalization. After 3 d of
incubation, 10 μL of CellTiter-Glo (Promega) was added to each well, in-
cubated for 10 min and the luminescence output was read on an M1000
Infinite Pro plate reader (Tecan). The entire experiment was independently
repeated twice (total of four compound plate replicates for each cell line) to
compile the results as reported.
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